Xeligekimab
Xeligekimab is a biopharmaceutical drug that is currently under development. It is a type of monoclonal antibody that is being studied for its potential use in the treatment of various autoimmune diseases.
Overview[edit | edit source]
Xeligekimab is a monoclonal antibody, which is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Monoclonal antibodies are used in the treatment of a variety of diseases, including cancer, autoimmune diseases, and infectious diseases.
Mechanism of Action[edit | edit source]
Xeligekimab works by targeting and binding to a specific protein in the body. This protein is involved in the inflammatory response, which is part of the body's immune system. By binding to this protein, Xeligekimab can help to reduce inflammation and the symptoms of autoimmune diseases.
Clinical Trials[edit | edit source]
As of now, Xeligekimab is still in the clinical trial phase. These trials are designed to test the safety and effectiveness of the drug in treating various conditions. The results of these trials will determine whether Xeligekimab is approved for use in the general population.
Potential Uses[edit | edit source]
If approved, Xeligekimab could be used to treat a variety of autoimmune diseases. These could include conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. However, more research is needed to determine the full range of conditions that Xeligekimab could potentially treat.
Side Effects[edit | edit source]
As with any drug, Xeligekimab may cause side effects. These could potentially include reactions at the injection site, allergic reactions, and other side effects. However, the specific side effects of Xeligekimab will not be fully known until the clinical trials are completed.
See Also[edit | edit source]
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
